Jürgen Dinger

No ORCID on file · 6 papers in corpus · active 2009-2020

Study types

  • article 6
article 2020
COCs containing dienogest and 30 µg ethinylestradiol may carry a higher VTE risk compared to corresponding preparations with levonorgestrel: A meta-analysis of four large cohort studies
·doi:10.15761/fwh.1000175

The European Medicines Agency requested a meta-analysis of four large, multi-national cohort studies on hormonal contraceptives to clarify whether dienogest/ethinylestradiol-containing combined oral contraceptives (DNG/EE) carry a different…

article 2020
Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study
·doi:10.15761/fwh.1000178
article 2017
Cardiovascular safety among users of different combined oral contraceptives — final results from the INAS-SCORE study
·doi:10.1016/j.contraception.2017.07.114
article 2016
Impact of estrogen type on cardiovascular safety of combined oral contraceptives
·doi:10.1016/j.contraception.2016.06.010
article 2010
Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
·doi:10.1783/147118910791749416

OBJECTIVE: The primary objective of the study was to clarify whether the use of the oral contraceptive 2 mg dienogest/30 microg ethinylestradiol (DNG/EE) is associated with a higher risk of venous thromboembolism (VTE) than the use of other…

article 2009
P750 Risk of venous thromboembolism and use of dienogest‐containing oral contraceptives – results from a case–control study
·doi:10.1016/s0020-7292(09)62241-4